Advanced Semantic Knowledge-Based Bio-Medical Search Solution

A web browser that can understand technical terms in life sciences and automatically find additional resources and services has been developed by European researchers. It could lead to a new generation of intelligent search engines. The life sciences community has built numerous databases - such as for gene sequencing and information about diseases - that are available to researchers as 'grid' services.

"Grid computing is essentially about building virtual organisations that are independent of the physical location where they reside," says Michael Schroeder of Technische Universität Dresden.

The problem is how to link those services to other scientific information found on the web. Schroeder is coordinator of the EU-funded Sealife project which has created a 'semantic grid browser' to make grid services for the life sciences much more accessible.

"We have the web on the one hand and then we have grid computing, with its many services, on the other," he says. "A semantic grid browser seamlessly integrates them.

"It tries to understand what it finds on web pages, interprets this content and then links it, on the fly, to services that might be useful to the user."

The key to the Sealife browser is a 'semantic hyperlink' that shows up on the page to direct users to relevant services. The link is not put there by the website but by the browser itself.

How does it do that?
First, the browser needs to understand the content of the page and identify terms which could be linked to grid services. An example tested in the Sealife project is the naming of genes. Each human gene has an average of 5.5 names, Schroeder points out, but if it can be identified correctly, a link can be made to a wealth of information about that gene.

The browser must also be able to handle ambiguity. "If I see 'Jaguar' on a web page, what is it? Is it an animal? Is it a car? Is it the Mac operating system?" Sealife uses specialised algorithms to work out the context from other words on the page and correctly interpret the meaning.

It is still not an exact science, though. The Sealife team entered their algorithm in an international competition with 50 others to identify names of genes. They won, with an 81% success rate, though Schroeder says they have now got that up to 87%.

Background knowledge
The second challenge is the background knowledge that allows the browser to make sense of the identified terms. Such knowledge is formally known as an 'ontology', a systematic hierarchy of concepts and their relation to one another. Biology, with its extensive taxonomies, is an ideal field for semantic grid browsing.

"All these efforts of building hierarchical classification systems have been at the core of biology for centuries," says Schroeder. "Biologists are used to it and there are many efforts to make information exchangeable."

But outside the life sciences such systematic classification is not so well developed, and the Sealife project has created editors to build ontologies from published literature in any specific field of interest.

"We developed algorithms that grind through this data, identify the key concepts and then the ontology editor offers these concepts to you," Schroeder explains. "If you agree, it then searches the web to find things that look like definitions. This whole process of building this background knowledge cannot be fully automated but you can ease the pain of doing this quite significantly."

Different varieties of the Sealife browser build on work by partners in Edinburgh, Manchester, London and Sophia-Antipolis, as well as in Dresden. They have been tested in three scenarios: evidence-based medicine, mining of scientific and patent literature, and in molecular biology. In each case, the focus has been on infectious diseases.

Browser that understands everything?
So successful has the project been that TU Dresden has spun-off a new company, Transinsight, to exploit work done in Sealife. The company has sold semantic browsers to such major customers as BASF and Unilever and runs the GoPubMed search engine, which is linked to the respected PubMed archive of biomedical literature.

But there is no reason why a semantic browser should be confined to specialised academic areas. Could we have a browser that understands everything? Schroeder thinks that is not as far-fetched as it may seem. "The vision is to include every domain," he says. "For example, if we were able to extract and formalise the knowledge in Wikipedia we would have this general background knowledge that covers all areas."

Many researchers look forward to a next-generation search engine that can understand what the user is looking for and return much more relevant results than today's engines can. "This will involve integrating information," says Schroeder, "because very often answers to questions are not provided in one document as a single statement that I can pick up by keywords.

"In the future, we will need background knowledge and this is at the core of Sealife. If we build semantic into search, and make it scaleable, then you will have the next-generation search engine."

The Sealife project received funding from the ICT strand of the EU's Sixth Framework Programme for research.

For further infoprmation, please visit:

Source: ICT Results

About Transinsight
Transinsight is focused on semantic software solutions in the area of knowledge- and meaning-based computing. The flagship product, GoPubMed PRO, a semantic biomedical search engine, is the first knowledge-based search engine for the Life Sciences on the Internet. The enterprise is headquartered in Dresden, Germany. Transinsight is ranked under the Top 5 biotech companies in Europe.

Most Popular Now

FDA approves Roche's OCREVUS™ (ocrelizumab) for re…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both ...

Read more

First collaborative definition of patient centrici…

AstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-d...

Read more

High doses of vitamin C to improve cancer treatmen…

Clinical trials found that it is safe to regularly infuse brain and lung cancer patients with 800 - 1000 times the daily recommended amount of vitamin C as a potential st...

Read more

Deep learning algorithm could boost drug developme…

Artificially intelligent algorithms can learn to identify amazingly subtle information, enabling them to distinguish between people in photos or to screen medical images ...

Read more

Bristol-Myers Squibb enters into separate agreemen…

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for ...

Read more

Tagrisso (osimertinib) receives US FDA full approv…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment...

Read more

A one-two punch hits pancreatic cancer where it hu…

Australian scientists have uncovered a promising new approach to treating pancreatic cancer, by targeting the tissue around the tumour to make it 'softer' and more respon...

Read more

FDA allows marketing of first direct-to-consumer t…

The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are ...

Read more

Novartis to strengthen R&D pipeline by in-lice…

Novartis has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing condi...

Read more

New drug delivery system shows promise for fightin…

A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiatio...

Read more

Towards a safe and scalable cell therapy for type …

More than 36 million people globally are affected by type 1 diabetes (T1D), a lifelong disorder where insulin producing cells are attacked and destroyed by the immune sys...

Read more

XELJANZ® (tofacitinib citrate) receives marketing …

Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination wi...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]